Benjamin F. Edwards & Company, Inc. Editas Medicine, Inc. Transaction History

Benjamin F. Edwards & Company, Inc.

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 27, 2023	BUY	$7.03 - $11.53 $260 - $426	37 Added 0.92%	4,054 $29,000
Q4 2022 Feb 07, 2023	SELL	$8.32 - $13.21 $440 - $700	-53 Reduced 1.3%	4,017 $36,000
Q3 2022 Oct 28, 2022	SELL	$12.16 - $19.42 $4,547 - $7,263	-374 Reduced 8.42%	4,070 $50,000
Q2 2022 Aug 12, 2022	SELL	$9.99 - $21.35 $23,316 - $49,830	-2,334 Reduced 34.43%	4,444 $53,000
Q1 2022 May 04, 2022	BUY	$14.08 - $27.63 $34,566 - $67,831	2,455 Added 56.79%	6,778 $129,000
Q4 2021 Feb 07, 2022	BUY	$26.55 - $40.57 $113,448 - $173,355	4,273 Added 8546.0%	4,323 $115,000
Q2 2020 Aug 14, 2020	SELL	$18.5 - $34.34 $3,700 - $6,868	-200 Reduced 80.0%	50 $1,000
Q4 2019 Feb 06, 2020	SELL	$19.49 - $32.63 $9,043 - $15,140	-464 Reduced 64.99%	250 $7,000
Q3 2019 Nov 05, 2019	SELL	$22.49 - $26.81 $32,453 - $38,686	-1,443 Reduced 66.9%	714 $16,000
Q2 2019 Aug 08, 2019	SELL	$20.48 - $27.76 $11,939 - $16,184	-583 Reduced 21.28%	2,157 $53,000
Q1 2019 May 15, 2019	BUY	$19.43 - $26.41 $5,770 - $7,843	297 Added 12.16%	2,740 $67,000
Q4 2018 Jan 31, 2019	SELL	$18.19 - $31.79 $17,280 - $30,200	-950 Reduced 28.0%	2,443 $56,000
Q3 2018 Oct 29, 2018	BUY	$27.65 - $38.39 $8,295 - $11,517	300 Added 9.7%	3,393 $108,000
Q2 2018 Jul 19, 2018	BUY	$31.4 - $41.01 $2,041 - $2,665	65 Added 2.15%	3,093 $111,000
Q1 2018 Apr 17, 2018	BUY	$29.84 - $44.08 $6,117 - $9,036	205 Added 7.26%	3,028 $100,000
Q4 2017 Jan 17, 2018	BUY	$21.89 - $31.34 $53,192 - $76,156	2,430 Added 618.32%	2,823 $87,000
Q3 2017 Oct 24, 2017	BUY	$15.81 - $24.01 $6,213 - $9,435	393	393 $9,000

244

56.8M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Benjamin F. Edwards & Company, Inc., based on Form 13F filings with the SEC.

Stay updated on Benjamin F. Edwards & Company, Inc. with notifications on news.